Evaluation of the Implementation of FDG-PET/CT and Staging Laparoscopy for Gastric Cancer in The Netherlands
- PDF / 397,986 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 33 Downloads / 186 Views
ORIGINAL ARTICLE – GASTROINTESTINAL ONCOLOGY
Evaluation of the Implementation of FDG-PET/CT and Staging Laparoscopy for Gastric Cancer in The Netherlands Emma C. Gertsen, MD1 , Alicia S. Borggreve, MD1,2, Hylke J. F. Brenkman, MD, PhD1, Rob H. A. Verhoeven, PhD3,7, Erik Vegt, MD, PhD4,5, Richard van Hillegersberg, MD, PhD1, Peter D. Siersema, MD, PhD6, Jelle P. Ruurda, MD, PhD1,8, and on behalf of the Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group 1
Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; 2Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; 3Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands; 4 Department of Radiology and Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands; 5Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 6 Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; 7 Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands; 8Department of Surgery, Division Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
ABSTRACT Background. The role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDGPET/CT) and staging laparoscopy (SL) has increased in the preoperative staging of gastric cancer. Dutch national guidelines have recommended the use of FDG-PET/CT and SL for patients with locally advanced tumors since July 2016. Objective. The aim of this study was to evaluate the implementation of FDG-PET/CT and SL in The Netherlands. Methods. Between 2011 and 2018, all patients who underwent surgery for gastric cancer were included from the Dutch Upper GI Cancer Audit. The use of FDG-PET/ CT and SL was evaluated before and after revision of the Dutch guidelines. Outcomes included the number of noncurative procedures (e.g. palliative and futile procedures) and the association of FDG-PET/CT and SL, with waiting times from diagnosis to the start of treatment.
Ó The Author(s) 2020 First Received: 23 January 2020 Accepted: 15 August 2020 J. P. Ruurda, MD, PhD e-mail: [email protected]
Results. A total of 3310 patients were analyzed. After July 2016, the use of FDG-PET/CT (23% vs. 61%; p \ 0.001) and SL (21% vs. 58%; p \ 0.001) increased. FDG-PET/CT was associated with additional waiting time to neoadjuvant therapy (4 days), as well as primary surgical treatment (20 days), and SL was associated with 8 additional days of waiting time to neoadjuvant therapy. Performing SL or both modalities consecutively in patients in whom it was indicated was not associated with the number of non-curative procedures. Conclusion. During implementation of FDG-PET/CT and SL after revision of the guidelines, both have increasingly been used in The Netherlands. The addition of these staging methods was associated with
Data Loading...
